Intrarosa vs Imvexxy: Which Vaginal Treatment for Painful Sex Is Right for You?
By The HRT Index Editorial Team · Independent editorial research — not medical advice, and not medically reviewed by a clinician. · Last verified: June 2026. Prices and label details change, so re-check before you pay.
Intrarosa and Imvexxy are both FDA-approved vaginal inserts for moderate-to-severe painful sex after menopause. The core difference: Imvexxy is a low-dose estrogen (estradiol). Intrarosa is prasterone — a form of DHEA — which the FDA label says your body converts into “active androgens and/or estrogens” inside the vaginal tissue(androgens are hormones like testosterone). One guideline gives vaginal estrogen the longer track record, but says there isn’t enough evidence to recommend one over the other.
So there’s no single “winner” we can hand you — and any page that claims there is one is guessing. What we cando is show you exactly how they differ, what each really costs in 2026, who each one tends to fit, and the few situations where the smartest move is to skip online care and see a clinician in person first. By the end, you’ll know which one to ask about — and what to verify before you pay a dollar.
Which one is even your conversation?
| If this sounds like you… | Ask your clinician about… |
|---|---|
| You want a low-dose vaginal estrogen, you’d rather skip an applicator, and twice-a-week dosing (after the first two weeks) appeals to you | Imvexxy |
| You’d rather try a non-estrogen active ingredient (prasterone/DHEA — though it still converts to estrogen and androgens locally), and a nightly insert fits your routine | Intrarosa |
| You have unexplained vaginal bleeding, a history of breast cancer, blood clots, stroke, or liver disease | Neither — on your own, online. Get evaluated in person first. |
| Your main problem is hot flashes, night sweats, or sleep — not just vaginal symptoms | Probably not this comparison. Start with whole-body (systemic) HRT options instead. |
Not sure which row is you?
That’s normal — it depends on details a chart can’t see. Use The HRT Index’s Find My HRT Path tool to match your situation in about 90 seconds, and to flag when you should see someone in person first.
Find My HRT Path →Is Intrarosa or Imvexxy actually better?
For most women, neither is clearly “better” — they’re two different tools for the same job.The 2025 GSM guideline from the American Urological Association and partner societies says low-dose vaginal estrogen has the strongest evidence base (it’s been studied the longest), but that there isn’t enough information to recommend one hormonal therapy over another. So the choice comes down to shared decision-making — your preference, your safety history, your cost.
Here’s the honest part most comparison pages skip: we can’t tell you which one will work better for you — and the medical guideline says it can’t either.There’s no head-to-head study crowning a winner, and anyone who promises you a simple “just take this one” answer is selling certainty they don’t have.
Both drugs are FDA-approved for this exact problem, and both beat placebo at easing painful sex in 12-week trials. Real-world satisfaction is nearly identical too: on Drugs.com, Intrarosa averages 5.3 out of 10 across 123 reviews and Imvexxy averages 5.2 out of 10across 74 reviews (all-comer ratings that include people who didn’t respond, stopped, or had cost problems — not proof that nearly half of users had a bad experience).
Intrarosa vs Imvexxy at a glance
The biggest differences are the ingredient, the schedule, the price path, and the safety screening. Last verified June 2026 — prices and label details change, so re-check before you pay.
| Decision factor | Intrarosa | Imvexxy |
|---|---|---|
| What it is | Prasterone 6.5 mg (a form of DHEA) — a non-estrogen active ingredient the label says is converted to “active androgens and/or estrogens” locally | Estradiol — a low-dose estrogen — in a 4 mcg or 10 mcg insert |
| FDA-approved for | Moderate-to-severe painful sex (dyspareunia) from vaginal atrophy due to menopause | The same — painful sex from vaginal atrophy due to menopause |
| FDA-approved (brand) | 2016 | 2018 |
| Treats hot flashes? | No — not FDA-approved for hot flashes or night sweats | No — not FDA-approved for hot flashes or night sweats |
| How you use it | One insert nightly, with a provided applicator | One insert daily for 2 weeks, then twice a week; placed with your finger (no applicator) |
| Inserts per month (maintenance) | About 28 | About 8 |
| Cash price (June 2026 snapshot) | About $322 for a 28-insert month (Drugs.com) | About $229 for an 8-insert maintenance pack and about $506 for the 18-insert starter pack (Drugs.com) |
| Manufacturer savings | As little as $35 per 28-day supply (eligible commercial-insurance patients; up to 12 uses) | Mayne Pharma savings card can go as low as $0 for eligible patients — out-of-pocket amounts vary; verify the live offer |
| Generic available? | No — brand only, none approved | Approved (Dec 2025) but not yet on the market — see cost section below |
| Most common side effect (per label) | Vaginal discharge; changes on a Pap smear | Headache |
| Big safety flags (per label) | Don’t use with unexplained vaginal bleeding; label warns about breast cancer history (it converts to estrogen) | Contraindicated with unexplained bleeding, known/suspected/history of breast cancer, active clots, stroke/heart-attack history, liver disease, or clotting disorders |
| Real-world rating | 5.3/10 (123 reviews, Drugs.com) | 5.2/10 (74 reviews, Drugs.com) |
Sources: FDA prescribing information for Intrarosa and Imvexxy (DailyMed); FDA first-generic approval (Teva), Dec 8 2025; Drugs.com price guides and user ratings; AUA/SUFU/AUGS 2025 GSM guideline.
What’s the real difference between Intrarosa and Imvexxy?
Imvexxy delivers estrogen. Intrarosa delivers a non-estrogen building block that your body converts into estrogen — and androgens — right where it’s needed. Both restore the thin, dry, fragile vaginal tissue that causes painful sex after menopause. They just take different routes to get there.
Imvexxy = vaginal estradiol. Estradiol is the main estrogen your ovaries made before menopause, released straight into the vaginal lining. It comes in a low 4 mcg dose — among the lowest vaginal estradiol doses available. Because it’s such a small dose, most of it works locally and only a little reaches the rest of your body. Some absorption can happen, though, which is exactly why the estrogen safety rules still apply.
Intrarosa = vaginal prasterone (DHEA). Prasterone is a lab-made version of DHEA, a natural hormone your body makes that drops as you age. On its own, it isn’t estrogen. But the nuance the marketing glosses over: the FDA label says your body converts prasterone into “active androgens and/or estrogens” inside the tissue, and the exact way it works in menopause isn’t fully understood. That’s the real, careful description — not “estrogen-free and risk-free.”
What the label actually says vs. what you might hear
| You might hear… | What the FDA label actually says |
|---|---|
| “Intrarosa is a non-estrogen treatment” | The active ingredient isn’t estrogen, but it’s “converted into active androgens and/or estrogens” in the body |
| “It’s natural / bioidentical” | It’s a prescription steroid; the mechanism in menopause “is not fully established” |
| “Vaginal estrogen barely absorbs” | Imvexxy is low-dose and mostly local, but “systemic absorption may occur” |
| “These treat menopause” | Both are approved only for painful sex from vaginal atrophy — not hot flashes or whole-body symptoms |
Nightly or twice-weekly: which is easier to live with?
Imvexxy is usually the lighter routine.After a two-week daily start, you drop to just two inserts a week. Intrarosa is one insert every night, with no step-down — and it uses an applicator, while Imvexxy you place with a finger. That convenience gap is real and worth weighing, because the best treatment is the one you’ll actually keep using.
| Use factor | Intrarosa | Imvexxy |
|---|---|---|
| First 2 weeks | Nightly | Nightly |
| After that (maintenance) | Nightly, ongoing | Twice a week (every 3–4 days) |
| Applicator? | Yes, included | No — placed by hand |
| Inserts per month | ~28 | ~8 |
| Best fit for | Someone okay with a steady nightly habit | Someone who wants fewer doses to remember |
A practical heads-up: both products can cause some discharge or a “melted” feeling overnight, since the inserts dissolve. It’s usually minor — many women insert at bedtime and wear a liner. If mess is a dealbreaker for you, raise it with your clinician before you choose.
What are the side effects of Intrarosa vs Imvexxy?
Both are generally well tolerated, and their most common side effects differ.Per the FDA labels, Intrarosa’s most common side effect is vaginal discharge (and sometimes changes on a Pap smear), while Imvexxy’s most common side effect is headache. Both are low-dose vaginal therapies, so side effects tend to be local and mild — but report anything unusual, especially vaginal bleeding, to your clinician.
- Intrarosa: Vaginal discharge and Pap-smear changes are the standouts in the label. Because it converts to hormones locally, some women also report hormone-type effects; everyone’s different.
- Imvexxy: Headache leads the label. As an estrogen, it carries the broader cautions of estrogen therapy (covered in the safety section below).
- Both: Real-world reviews mention a wider range of individual experiences than the label’s “most common” list. That’s normal, and it’s exactly why your own clinician should track how you respond over the first couple of months.
Side effects are personal. If one product doesn’t sit right with you, that’s useful information for switching — not a sign you’ve failed.
How much do Intrarosa and Imvexxy cost in 2026?
With commercial insurance and a savings card, both can drop to a low monthly cost — close to a tie. Paying cash, Intrarosa runs about $322 a month, and Imvexxy is similar (a pricier starter pack, then cheaper maintenance) — and despite a generic being approved, there’s no cheaper generic on shelves yet. Coupons and insurance can flip the answer, so verify yours before you pay.
| Price item | Snapshot (Drugs.com, June 2026) | What it means |
|---|---|---|
| Intrarosa, 28 inserts | ~$322 | A full nightly month |
| Imvexxy maintenance, 8 inserts | ~$229 | A maintenance month after the first two weeks |
| Imvexxy starter pack, 18 inserts | ~$506 | Your first month only |
Commercial insurance and copay cards
If you have commercial (non-government) insurance, savings cards do the heavy lifting. Intrarosa’s program lists out-of-pocket cost as low as $35 per 28-day supply for eligible patients (up to 12 uses). Imvexxy’s Mayne Pharma savings card can lower the cost for eligible commercially insured patients too — some terms list as little as $0— but the official cost page notes out-of-pocket amounts can vary, so confirm the current offer when you fill.
Medicare and cash-pay traps
Commercial copay cards almost always exclude Medicare, Medicaid, and other government plans.That’s where the cost cliff hits — often right at age 65. One Imvexxy reviewer on Drugs.com described the price jumping to “over $200 a month” out of pocket once Medicare entered the picture, with no coverage. (That’s one person’s experience, not a price quote for everyone — but it’s exactly the kind of surprise we want you to see coming.)
If you’re on Medicare, there’s one extra option worth knowing: Intrarosa has a separate savings pathway for Medicare patients — as little as $85per 28-day supply — though it has its own terms and isn’t the same as the commercial card. Ask the manufacturer or your pharmacist whether you qualify.
Generic Imvexxy: approved vs. actually available
This is the cost detail almost every other page gets wrong. The FDA approved the first generic version of Imvexxy (made by Teva) on December 8, 2025. That’s real. But as of mid-2026, Drugs.com shows no pricing for it and notes it does not appear to be commercially available yet — and the brand’s patents run to 2032. So a cheaper generic Imvexxy could still be years away.
The safety question: when should you not start either one online?
Some situations should be evaluated in person before you start any vaginal hormone — full stop. Think of the table below as a stoplight: green means online care may fit, yellow means ask a clinician first, red means get seen in person before you start anything.
| Your situation | Signal | What to do |
|---|---|---|
| Unexplained vaginal bleeding after menopause | 🔴 Red | See a clinician in person before starting anything — the cause needs to be found first |
| Breast cancer — now, past, or suspected | 🔴 Red | Imvexxy is contraindicated; Intrarosa carries a warning. Oncology/clinician decision, not a self-pick |
| Blood clots (DVT/PE), stroke, or heart attack history | 🔴 Red | These are contraindications for estrogen like Imvexxy. Clinician review first |
| Liver disease or a clotting disorder | 🔴 Red | Listed contraindications for estradiol. Get evaluated first |
| Other conditions estrogen can affect (migraine, lupus, diabetes, thyroid, gallbladder) | �DFE1 Yellow | Usable for many women, but flag it so your clinician can weigh it |
| Only local symptoms (dryness, pain with sex) and no red flags | 🟢 Green | Low-dose vaginal therapy is likely the right category — compare the two here |
| Hot flashes, night sweats, sleep, mood are the main issue | �DFE1 Yellow | Local inserts won’t treat these — look at systemic HRT instead |
A significant 2025–2026 FDA update worth knowing
In late 2025 and early 2026, the FDA began removing the “boxed warning” from menopausal hormone products — the broad warning about heart disease, breast cancer, and dementia that scared a generation of women away. The FDA requested the changes in November 2025, and in February 2026 it approved updated labels for six menopausal hormone products, including a topical vaginal estrogen. The Menopause Society agreed with removing the boxed warning on low-dose vaginal estrogen and said it may have been a deterrent to a safe, effective treatment.
Two things to keep straight: (1) Removing the broad boxed warning is not the same as removing the specific contraindications. Active breast cancer, unexplained bleeding, and recent clots are still real reasons not to use estrogen. (2) Imvexxy’s own label still shows the boxed warning right now— it wasn’t in that first batch of six. Read the current insert that comes with your prescription, and ask your pharmacist what’s changed.
This is the kind of detail that decides whether online care is even right for you. Our tool is built to flag it before you book →
Can you use Intrarosa or Imvexxy if you’ve had breast cancer?
Please don’t make this call from a website — including ours.This is a clinician-and-oncology decision, not a checkout-cart decision. Here’s the verified picture:
| Product or source | What it says about breast cancer |
|---|---|
| Imvexxy | Contraindicated in women with known, suspected, or a history of breast cancer |
| Intrarosa | Label warns about breast-cancer history, notes estrogen is a byproduct of prasterone, and states it has not been studied in women with breast cancer |
| The Menopause Society | Low-dose vaginal estrogen or DHEA may be an option for some women with a history of breast or uterine cancer — only through shared decision-making with primary care and oncology |
So “non-estrogen” does not make Intrarosa the automatic safe choice here. For many breast cancer survivors, non-hormonal options — good vaginal moisturizers and lubricants — are the usual first step, and any hormonal option is an individual decision made with your oncologist. Our tool routes you to in-person care first when that’s the safer call →
Which is better for your specific problem?
It depends on what’s actually bothering you.For the exact thing both drugs are approved to treat — painful sex from menopause-related vaginal atrophy — either belongs in the conversation. For other symptoms, the right answer may be bigger than these two products.
- Painful sex (dyspareunia): This is the bullseye for both. Either is reasonable to ask about.
- Vaginal dryness, burning, irritation: Both fit. These are part of GSM — genitourinary syndrome of menopause — the cluster of vaginal, vulvar, and urinary changes that come from lower estrogen. Unlike hot flashes, GSM tends to get worse over time without treatment, not better.
- Recurring UTIs or urinary urgency: GSM can drive these, and treating the tissue sometimes helps. But neither drug is FDA-approved to prevent UTIs, so let your clinician decide. Don’t treat a UTI yourself with a hormone insert.
- Hot flashes, night sweats, brain fog, sleep, low mood: These are whole-body symptoms. Local inserts aren’t meant to treat them. If this is your main issue, you’re looking at the wrong comparison — start with systemic HRT options instead.
Which one fits you?
Match the product to your priorities — estrogen comfort, dosing, and budget — then confirm the choice with a clinician. Neither of these is a prescription you give yourself; think of the lists below as what to ask about.
Lean toward Imvexxy if…
- ✓You’re comfortable using a low-dose estrogen and want a small 4 mcg dose.
- ✓Twice-a-week maintenance matters to you, and you’d rather skip an applicator.
- ✓You have commercial insurance and may qualify for the savings card.
Probably not your first pick if you have a breast cancer history, unexplained bleeding, a clot/stroke history, or liver disease (label contraindications), or if your real problem is hot flashes.
Lean toward Intrarosa if…
- ✓You’d rather try a non-estrogen active ingredient (prasterone/DHEA), even knowing it converts to estrogen and androgens locally.
- ✓A nightly insert fits your routine, and you don’t mind an applicator.
- ✓Your clinician specifically thinks prasterone/DHEA suits your symptom pattern.
Probably not your first pick if nightly dosing feels like too much, discharge is a dealbreaker, you have unexplained bleeding, or you have (or think you may have had) breast cancer without specific guidance from your doctor.
What do real women say about each one?
Satisfaction is mixed for both — and remarkably similar.On Drugs.com, Intrarosa scores 5.3/10 (123 reviews; 39% positive, 41% negative) and Imvexxy scores 5.2/10 (74 reviews; 36% positive, 41% negative). Read that as: plenty of women get real relief, plenty don’t, and it can take weeks to know. Reviews are helpful for spotting friction — they are not proof a drug will work or is safe for you.
The patterns worth knowing before you start:
- Cost and coverage come up constantly — surprise pharmacy prices, denied claims, and the Medicare cost cliff covered above.
- Discharge/mess shows up for both, since the inserts dissolve. Usually minor, occasionally annoying.
- Patience is a theme for Intrarosa especially — several reviewers say relief built slowly over months.
- Side effects vary by person. Per the FDA labels, Intrarosa’s most common is vaginal discharge and Imvexxy’s is headache; individual reviews mention more, which is why your own clinician should track how you respond.
How do you actually get Intrarosa or Imvexxy prescribed?
Both are prescription-only, so your next step is a clinician who treats menopause-related vaginal symptoms.If you want to use insurance, a telehealth menopause practice that bills insurance is the most direct route. If you’re paying cash, a cash-pay menopause visit works too. The exact product you walk away with is a shared decision — a good clinician may suggest a different vaginal estrogen that fits you better, and that’s a feature, not a bug.
| Provider | Best fit | Payment model | Verified |
|---|---|---|---|
| Midi Health | Using insurance for FDA-approved care | Bills insurance for virtual visits and prescriptions | June 2026 |
| Sesame | Paying cash, no insurance hassle | Cash-pay; does not bill insurance for care | June 2026 |
We can’t promise any clinician will prescribe one specific brand — the product is their clinical call. Confirm current pricing and your state at intake.
How we verified this comparison
We built this using The HRT Index Verification Standard— our documented process: read every published price, keep FDA-approved and compounded options strictly separate, verify availability and coverage claims, and re-check on a fixed schedule (top items monthly, the full roster quarterly). We evaluate on five things, always in this order: clinical legitimacy, care quality, medication fit, price transparency, and access. We don’t invent scores.
What we verified (June 2026):the FDA prescribing information for both drugs (ingredient, approved use, dosing, side effects, contraindications); the December 2025 first-generic Imvexxy approval and its not-yet-available status; the 2025–2026 FDA boxed-warning changes, including that Imvexxy’s own label still shows the warning; the AUA/SUFU/AUGS 2025 GSM guideline; the Menopause Society’s GSM guidance; the public cash-price snapshots and savings-card terms; and the real-world rating counts.
What we did not verify, and you should: your exact insurance coverage, your local pharmacy’s stock and price, your personal eligibility, whether a specific clinician will prescribe a given brand, and — because there’s no head-to-head trial — which drug will work better for you.
Intrarosa vs Imvexxy: frequently asked questions
Is Intrarosa estrogen?▼
No. Intrarosa’s active ingredient is prasterone, a form of DHEA, not estrogen. But the FDA label says the body converts it into active androgens and/or estrogens inside the vaginal tissue, and the exact way it works isn’t fully understood. That is why it still carries a breast-cancer warning.
Is Imvexxy estrogen?▼
Yes. Imvexxy is a low-dose vaginal estradiol insert (4 mcg or 10 mcg). Estradiol is a form of estrogen.
Which is better, Intrarosa or Imvexxy?▼
No major guideline crowns a winner. The 2025 AUA/SUFU/AUGS guideline says vaginal estrogen has the strongest evidence base but that there isn’t enough information to recommend one hormonal therapy over another. The better choice depends on your estrogen comfort, dosing preference, cost, and health history, decided with a clinician.
Which is cheaper, Intrarosa or Imvexxy?▼
With commercial insurance and a savings card, both can be very low (Intrarosa lists as little as $35; Imvexxy’s card can go as low as $0 for eligible patients, so verify). Paying cash, both run a few hundred dollars a month, and there isn’t a cheaper generic on shelves yet despite one being approved.
Is there a generic for either one?▼
Imvexxy: a generic was FDA-approved in December 2025, but as of mid-2026 it isn’t commercially available, has no listed price, and brand patents run to 2032. Intrarosa: no generic exists and none has been approved.
Which is less messy, Intrarosa or Imvexxy?▼
There is no universal answer. Imvexxy skips the applicator and has fewer doses, but reviewers still mention discharge, and Intrarosa users mention it too. Treat it as a personal-preference question; many women use a liner at bedtime.
How long do Intrarosa and Imvexxy take to work?▼
Imvexxy may bring relief as early as two weeks. Both were studied over 12 weeks, and it can take 8 to 12 weeks to feel the full effect, sometimes longer for Intrarosa per user reviews. Don’t quit too early.
Do Intrarosa or Imvexxy help with hot flashes?▼
No. Both are low-dose vaginal treatments approved only for painful sex from vaginal atrophy. They aren’t approved for whole-body symptoms like hot flashes or night sweats, which need a different systemic treatment.
Can I switch from Intrarosa to Imvexxy or back?▼
Often yes, but only with a clinician, because switching changes the ingredient, the schedule, the safety considerations, the cost, and sometimes insurance coverage.
Are compounded bioidentical vaginal hormones the same thing?▼
No. Compounded vaginal hormones are not FDA-approved and aren’t reviewed for safety, effectiveness, quality, and labeling the same way FDA-approved products are. The Menopause Society generally doesn’t recommend them for routine GSM care. Intrarosa and Imvexxy are FDA-approved products.
Still not sure which HRT program is right for you?
Take our free matching quiz — it takes about 90 seconds, it flags when you should see someone in person first, and you’ll walk into your consult knowing exactly what to ask.
Start Find My HRT Path →Related reading on The HRT Index
- Vaginal estrogen options compared
- Vagifem vs Imvexxy: Cost & Generic (2026)
- Estring vs Vagifem: Ring or Tablet? (2026)
- GSM treatment online: 2026 costs & options
Sources
- FDA / DailyMed — Intrarosa (prasterone) prescribing information
- FDA / DailyMed — Imvexxy (estradiol) prescribing information, including boxed warning
- FDA — First generic Imvexxy approval (Dec 8, 2025)
- Drugs.com — Generic Imvexxy availability & patents
- FDA — Labeling changes / boxed-warning removal for menopausal hormone therapy
- AUA / SUFU / AUGS — Guideline on Genitourinary Syndrome of Menopause, J Urol 2025 (PMID 40298120)
- The Menopause Society — comment on FDA hormone-therapy announcement
- Drugs.com — Intrarosa price guide
- Drugs.com — Imvexxy price guide
- Imvexxy official cost & safety information
- Drugs.com — Intrarosa user reviews
- Drugs.com — Imvexxy user reviews